Every article, report, and earnings note where GSK appears.
2 articles
GSK is leaning on specialty medicines, Shingrix, and a strong HIV franchise to offset declines in legacy categories. The stock looks fairly valued with modest upside, making it more of a steady Hold than a high-conviction buy.
GSK plc (GSK) fell after Q1 2026 results despite beating sales and profit forecasts. Investors focused on the quality of the beat, with much of the upside tied to legal settlement provisions and mixed segment trends across vaccines and medicines.
Generate an AI-powered research report — grades, price targets, financials, and chart analysis on demand.
Generate GSK ReportCancel anytime